Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think that comment could potentially mean something real, fbg. Its interesting though that no comments were made about delivering for shareholders when DOC, Petit, Bonstein, Fidelity, Adage, Blackrock etc. were buying over the years but......they sold just before things were getting interesting with petx approval and EU approval on the horizon, and HOT? Not complaining one bit...let the good news roll...EU partnership coming soon along with hopefully a huge HOT deal or BP deal. Either or, the valuation of this company is a joke and an appreciation HAS to occur. #frustrating
Heck ya!!
If I only had the time and the money, I could grow some awesome vines. GO ADXS!!... GLTAL's!
The market has a funny way of turning logical decision making against shareholders, ie. when to sell or buy. Best of luck to you and your decision to sell but I find it extremely hard for myself to sell at this time/price. Far too many catalyst coming in the next 6 months. GLTU, I for one am holding...HOT deal is coming soon.
Frozen distribution? Since when does an ADXS immunotherapy need to be frozen? Also, veterinarians receive their drugs every day in slightly sub frozen or equal to 32 degree temps ....and how frozen is frozen? My freezers cool to -20 degrees. Is a live attenuated vaccine effective in drastic temperature differences? I would doubt the heck out of it, but as always we will wait and see what happens.
I had to put my crazy ass, snaggle tooth, definitely one owner, bad arse boxer/pit mix down, at his peak in life after he tried to bite (more like scraped the face) of my daughter. I couldnt live with myself if he actually bit her and was waaaay to crazy to adopt out. Whenever he would lay down for the night he would groan for some 10 seconds...darndest thing if you actually saw it. I bought him a greasy cheeseburger and a strawberry shake and had to put him down. Buried him in wrapped in my favorite shirt. Life sucks sometimes. My 2,000 lb. bull I had to put down in January was just as tough and would make grown men cry if I told it, but thats for another time and place.
Plain and simple..YES! They did not expect a 20% drop after the announcement.
You missed the point entirely, raja.
Very wise of PETX to retract the shelf offering. This could be an example of mngmt indeed not knowing how their actions will reflect the shp. But I really like the "whoops...nevermind" announcement, lol. Anyone want to make a bet the stock will go up 20% tomorrow?
"In general, the Agency will issue an opinion on its evaluation within 210 'active' days. However, the clock may be stopped during the procedure to allow companies to answer questions posed by the Agency's Committees. This leads to the actual evaluation time being longer."
"The European Commissionfollows the opinion of the Agency in almost all cases. It takes around two months (60 days) for the European Commission to approve a medicine after the Agency has given a positive opinion."
Also, i found this below under the FAQ "How can i keep up to date with the agency's opinions" for those that may want to subscribe. i didnt have time to look any further into it.
"After every meeting of the main human and veterinary committee meetings, the Agency issues a news release with highlights of the meeting. To stay up to date with the latest news, features and publications from the Agency, you can subscribe to our RSS feeds.
The Agency also publishes a monthly newsletter called 'human medicines highlights'. This newsletter provides key information on the Agency's recent activity on human medicines."
Happy Thanksgiving y'all! Its been a LONG road for some of us... Here's to a truly happy ending that we can all be thankful for, on the road to come, for the Longtermer's, patients, and the team at Advaxis!
So... very little milestones unmet in 2014,2015, and 2016. Thanks for the feedback.
I remember the majority of timelines being reached on schedule in 2016, 2015, and 2014.
European Medicines Agency Committee Classifies Advaxis’ Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product
July 18, 2016
PRINCETON, N.J., July 18, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that its lead Lm immunotherapy candidate, axalimogene filolisbac (AXAL), has been classified as an advanced-therapy medicinal product (ATMP) for the treatment of cervical cancer by the European Medicines Agency’s Committee for Advanced Therapies (CAT).
“Classification of AXAL as an ATMP is reflective of a groundbreaking new opportunity for the treatment of HPV-associated cancers,” said Robert Ashworth, PhD, Vice President, Regulatory Affairs. “Building upon the approach endorsed at Advaxis’ meetings with National Competent Authorities earlier this year, it allows us to take advantage of a specific EU regulatory framework, akin to fast-track in the United States, designed to facilitate the review, approval, and access of AXAL in the EU market.” In the next phase of this regulatory process, CAT assessment of currently available quality and non-clinical data may help resolve some issues prior to the submission of a marketing-authorization application (MAA).
The Committee for Advanced Therapies is the committee at the European Medicines Agency that is responsible for classifying and assessing the quality, safety and efficacy of advanced-therapy medicinal products and following scientific developments in the field. It is a multidisciplinary committee, gathering together some of the best available experts in Europe. The ATMP designation is a classification for certain medicines for human use that are gene-, cell-, or tissue-based. The main responsibility of the CAT is to prepare a draft opinion on each ATMP application submitted to the European Medicines Agency, before the Committee for Medicinal Products for Human Use (CHMP) adopts a final opinion on granting a marketing authorization for the product. During drug development, CAT also reviews and certifies the acceptability of quality and non-clinical data.
Remember we also received EU equivalent to fast track designation which shaves some time off of the review process...i think 2 or 3 months.
Data overload for a small town redneck on a late Friday night, but thanks for the info/link.
I was thinking if they accepted a larger upfront and sacrificed smaller royalties down the road which is why I said $200. We need money very soon and we need a lot of it. An offering at these prices would decimate investors which also includes Advaxis employees.
What (realistically) would be the most upfront we could get for licensing HOT? Lombardo seemed to really be pushing the HOT construct today similar to DOC with NEO before the Amgen deal. I'm thinking maybe they are trying to monetize it with a very large upfront payment ($200 million?) to delay or even eliminate the need of an offering. If we can get a large upfront licensing deal inked in a couple months and then add EU partnership and also with k9 osteo approval the shp price could really explode. Again, what's the most y'all think we can get upfront for HOT??
Check the latest sc 13g.
Bonnstein and Petit getting paid bank!! Their shares/options are being doubled and tripled this year...
Wow, so the glass is not half full but close to overflowing with goodness and news to come..? yep, nothing has changed at all EXCEPT THE TUTES ARE UNLOADING!! Amgen will be buying us out any day now, lolol.
"Probably no human at Adage even looks at ADXS. It is such a small % holding for them that they probably let their computers make buy and sell decisions. And here we have ppl postulating bizarre theories of criminal conspiracies and illegal manipulation? " You hit the nail right on the head.
I think the tree has shaken a few long believers loose of their shares but the short numbers is where the real "information" is at, imo. If short numbers continue drop as we will see soon, it is truly an inflection point irregular to what has occurred in the past 3 years....if one felt so inclined to check.
I thought Petit and Bonstein just had their RSU's doubled in late June, 2017?? Did they just get awarded 100,000 more shares less than 5 months later????
Mp, i believe Lombardo said they were currently in discussions with potential partners in EU. (i suck at verbatim off of memory so check it). Listen to Lombardo's so called presentation. It was sub par on many peoples levels including mine.
Thanks, gb. eom
I always wondered why Amgen was not listed as a major holder in Advaxis. They were required to purchase about $50 million in shares. Any reason they are not listed?
2 new job listings posted 2 hours ago:
Scientist ll
Candidate will be responsible for the for execution, interpretation, and trouble-shooting of molecular biology and microbiology-based laboratory work and experiments in support of advancing our Listeria based immunotherapies. Candidate should be prepared to follow established protocols, identify and incorporate improved methods, analyze data, and keep meticulous notes.
Research Scientist, Protein Chemistry
The Research Scientist, Protein Chemist, is responsible for protein purification and nanoparticle formulation. The major responsibility includes prokaryotic cell culture, protein expression and purification, protein characterization and assay development, nanoparticle formulation and characterization. The candidate works closely with immunology group to evaluate novel cancer therapeutics in preclinical models. The Research Scientist is a key member Research & Development team and will work in a highly matrixed environment.
Responsibilities
Responsibilities-
Prokaryotic cell culture (E. coli. and others)
Protein expression and purification using GE AKTA system.
Protein characterization and quantification including but not limited to: SDS-PAGE, western blot, ELISA, and other bioassays.
Nanoparticle formulation with distinct properties
Particle characterization including size, load, property and biofunction.
Communicate effectively with research leader. Report research results to the research team.
Maintain detail and organized records.
ummm, no.
Short interest down 22% (-2,167,940 shares) and the shp is down 35% in the past month.
if you look at the short numbers and compare them to the stock price starting late 2014 you will see that as the shp increased so did the short %. The stock didn't rise to $30 and get massively shorted. It was being shorted more and more the whole way up.
Does anyone know of a company targeting hpv caused cancers of the head and neck?
Terry, thank you for posting. You remind me a lot of my father. He will be turning 80 soon but is sharper than most.
Best, tx
I will add a bit to the conspiracy theories. Bonstein and Petit's total stock holdings were doubled in about 6 months. Doc's holdings were also doubled. The stock options were granted doubling their holdings to all 3 at around the same time and about 3 weeks before before Dan's "resignation/departure." My first thought reading into the timings was it seemed like a farewell or like a job well done awarded to the CEO, CFO, and CSO before a sale of the company or a major transition. The timing and the amounts seem very odd
not related to us though, Ira1
It takes bizalls and bourbon to buy more today. I did both. Too much nonsense going on with shp and tutes. I think (hope) and am betting on short #'s dropping next week. We will see.
Adage selling again and other major tutes are gone... former CEO is gone...EMA submission delayed... PETX by no means is a sure thing before year end...company is silent...bordering 52 week lows. This stock could actually turn around into huge gains (miracles do happen) but it is not looking good my any means.
Adage sold 600,000 shares yesterday.
Nasdaq shows 5 trades/100 shares each for $1.52 and down 18%..? I like your numbers better though.